September 26, 2024

TerraTrust nominated for the DQS Sustainability Award 2024 in the “Sustainable Innovation” category

TerraTrust nominated for the DQS Sustainability Award 2024 in the “Sustainable Innovation” category

We are pleased to announce significant news: the first sustainable and biodegradable pregnancy test in Europe developed by Zamann Pharma Support, under the Terra Trust house brand, has been nominated for the prestigious DQS Sustainability Award 2024 in the “Sustainable Innovation” category. This nomination is a confirmation of their tireless commitment to environmental protection and sustainable innovation.

Every year, the DQS Sustainability Awards recognize companies that are pioneers in sustainability. It is one of the most important awards in the field of sustainability, recognizing companies, regardless of their size, for their innovative approaches to promoting environmental protection and social responsibility. This nomination is not only a recognition for Terra Trust, but underscores how necessary sustainable solutions have become in all areas of life, including the healthcare industry.

For Terra Trust, this nomination symbolizes much more than just a recognition of their technical innovation. It highlights the growing importance of environmental protection in a sector traditionally characterized by plastic waste and environmentally harmful disposables. Their product represents a new generation of pregnancy tests that protect the environment without compromising on quality or accuracy.

More Information in German / Original News:

Our latest News

discover more
Hummingbird Diagnostics Showcases New Data Utilizing Blood-Based Small RNA for Lung Cancer Treatment Monitoring at ESMO Congress 2026

Hummingbird Diagnostics Showcases New Data Utilizing Blood-Based Small RNA for Lung Cancer Treatment Monitoring at ESMO Congress 2026

Study demonstrates the ability of small RNA to inform lung cancer treatment strategies HEIDELBERG, Germany, October 26, 2026 – Hummingbird Diagnostics GmbH, a pioneer in blood-based small RNA biomarker discovery and assay development, today announced new clinical data demonstrating the ability of small RNA to enable adaptive treatment strategies in lung cancer patients. The results […]

Newsletter der BMBH: Biobanking Update!

Newsletter der BMBH: Biobanking Update!

Informationen über unsere Aktivitäten und aktuelle Entwicklungen im Biobanking am Standort und darüber hinaus. IN DIESER AUSGABE__Die BMBH im ÜberblickAktuelles aus der BMBHAktuelles aus denMitgliedsbiobankenNationale / InternationaleBiobanking-AktivitätenPublikationenAnstehende Termine

Huntington’s Disease Biomarkers: Key Molecular Targets and Antibody Tools for HD Research

Huntington’s Disease Biomarkers: Key Molecular Targets and Antibody Tools for HD Research

Proteins to Watch in Huntington’s Disease Research When developing assays to study Huntington’s disease (HD), scientists have a rare advantage: they know the exact genetic cause. But that hasn’t made the biological mechanism any easier to tackle. Despite decades of research, effective treatments remain limited for this progressive degenerative disease.2 HD is inherited in an autosomal-dominant […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp